Imfinzi OverviewDurvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or follow...
Read more Imfinzi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Durvalumab
Recent Imfinzi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 50mg/ml
NDC Database Records for Imfinzi: (2 results)Sorted by National Drug Code
- 0310-4500 Imfinzi 120 mg/2.4ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp
- 0310-4611 Imfinzi 500 mg/10ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp